RxDoctor Payments Data

Angela Christensen, MD

Rheumatology · Edinburg, TXNPI 1699031278

Payments from drug & device makers

$3,942in general payments, 2019–2025

Across 205 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$826
  • AbbVie$742
  • Amgen$717
  • ANI Pharmaceuticals, Inc.$263
  • E.r. Squibb & Sons, L.L.C.$247
  • Aurinia Pharma U.S., Inc.$224
  • plus $923 from 9 others

What the payments were for

  • Food & beverage$3,84397%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,942 in reported general payments places this provider in the 45th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas

Medicare billing

Part B allowed, 2024
$8,067
Medicare patients
34
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab166$1,124,843
RinvoqUpadacitinib99$622,071
Enbrel SureclickEtanercept78$563,376
Cosentyx Unoready PenSecukinumab13$202,150
SimponiGolimumab34$197,552
KevzaraSarilumab44$188,250
Orencia ClickjectAbatacept29$171,709
OtezlaApremilast25$121,706
Humira PenAdalimumab15$93,705
Xeljanz XrTofacitinib Citrate13$71,621
Hydroxychloroquine Sulfate271$8,029
Leflunomide134$4,620
MethotrexateMethotrexate Sodium242$3,768
Cevimeline Hcl26$3,482
Febuxostat14$1,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$742$622,07199 claims
Johnson & JohnsonSimponi$826$197,55234 claims
SanofiKevzara$145$188,25044 claims
AmgenOtezla$717$121,70625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 512 rheumatology providers in Texas.

Other rheumatology in Edinburg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →